Loading...
Loading...
Analysts at Goldman Sachs downgraded
Impax Laboratories Inc.IPXL from Buy to Neutral.
The price target for Impax Laboratories has been raised from $33.00 to $41.00.
Impax Laboratories shares have climbed 77.61% over the past 52 weeks, while the S&P 500 index has surged 13.71% in the same period.
Impax Laboratories' shares declined 0.33% to close at $39.11 yesterday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in